Johnson & Johnson announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra, or JNJ-2113, the first targeted oral peptide that selectively blocks the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback